Welcome to our dedicated page for Surrozen SEC filings (Ticker: SRZN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Surrozen filings document a biotechnology issuer focused on Wnt signaling and antibody technologies for ophthalmic disease. Recent Form 8-K reports disclose operating results, financial condition, pipeline business updates for SZN-8141 and related retinal disease programs, and collaboration and license revenue tied to research milestones.
The company's regulatory reports also record governance and compensation matters, including board and executive changes and inducement equity arrangements, along with material-agreement disclosures such as the termination of the TCGFB collaboration for antibody discovery services. Cover-page data and exhibits identify Surrozen common stock and redeemable warrants as part of the public-company capital structure.
Surrozen, Inc. ownership is reported jointly by Boxer Capital Management, LLC and related entities. The filing states the Reporting Persons beneficially own 766,318 shares of common stock as of March 31, 2026, representing 6.67% of the class based on 11,486,707 shares outstanding as of March 19, 2026.
The cover data shows shared voting and shared dispositive power for the 766,318 shares; signatures are dated May 15, 2026.
Surrozen, Inc. reports beneficial ownership of 525,639 shares, representing 4.5% of its common stock. The amount consists of 195,981 shares of common stock and 329,658 shares issuable upon exercise of warrants. Shares outstanding were 11,486,707 as of March 19, 2026, and warrant counts include Series A, Series B and Series E warrants; ownership is subject to a 9.9% beneficial ownership limitation.
Surrozen, Inc. director Mace Rothenberg received a grant of stock options as part of board compensation. The award covers 5,550 options to purchase Common Stock at an exercise price of $30.14 per share. The options vest and become exercisable on the anniversary of the May 13, 2026 grant date, conditioned on continuous service as a director, and expire on May 12, 2036. Following this grant, Rothenberg holds 5,550 options directly.
Surrozen, Inc./DE director David J. Woodhouse received a grant of 5,550 stock options, giving him the right to buy 5,550 shares of Common Stock. The options have a conversion or exercise price of $30.14 per share and expire on May 12, 2036. According to the terms, the options vest and become exercisable on the anniversary of the grant date, subject to his continuous service as a director. After this grant, he holds 5,550 director stock options directly, and this filing reflects a compensation-related award rather than an open-market share purchase or sale.
Surrozen director Mary Haak‑Frendscho received a grant of 5,550 stock options. These Director Stock Options give her the right to buy 5,550 shares of Surrozen common stock at an exercise price of $30.14 per share. The options vest on the anniversary of the May 13, 2026 grant date, as long as she continues serving as a director, and will expire on May 12, 2036 if not exercised.
Surrozen director Christopher Y. Chai received a grant of stock options covering 5,550 shares of common stock. The options carry an exercise price of $30.14 per share and expire on May 12, 2036. They vest and become exercisable on the anniversary of the May 13, 2026 grant date, subject to his continuous service as a director. Following this compensation-related award, his directly held option position reported in this filing totals 5,550 options.
Surrozen, Inc. director Eric Bjerkholt received a grant of stock options covering 5,550 shares of common stock. The options have an exercise price of $30.14 per share and expire in 2036. According to the terms, they vest and become exercisable on the anniversary of the grant date, subject to his continuous service as a director.
Surrozen, Inc. director Anna Berkenblit received a grant of 5,550 stock options classified as a derivative award. The options have an exercise price of $30.14 per share for Surrozen common stock and are held directly. Following this grant, she holds 5,550 options of this award.
The options vest and become exercisable on the anniversary of the grant date, conditioned on her continuous service as a director, and are scheduled to expire on May 12, 2036. This is a compensation-related grant, not an open-market share purchase or sale.
Surrozen, Inc. reported the results of its 2026 Annual Meeting of Stockholders. Of 11,486,707 shares entitled to vote as of March 18, 2026, 7,744,669 were represented in person or by proxy. Stockholders elected Mace Rothenberg, M.D., and David J. Woodhouse, Ph.D., as Class II directors until the 2029 Annual Meeting, subject to earlier departure. They also ratified Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2026. On an advisory basis, stockholders approved the compensation of the named executive officers and chose to hold future advisory votes on executive compensation every year.
Surrozen reported a much larger net loss of $127.5 million for the three months ended March 31, 2026, driven mainly by non‑cash fair value losses on a tranche liability and warrant liabilities linked to its 2025 private placement. Revenue rose to $5.0 million, primarily from a $5.0 million research milestone earned under its collaboration with Boehringer Ingelheim. Operating expenses increased as the company advanced ophthalmology programs, including SZN‑8141 and SZN‑8143. Surrozen ended the quarter with $106.9 million in cash and cash equivalents and used $12.5 million in operating cash. It raised $26.9 million via an at‑the‑market equity program and has a contingent second PIPE tranche of about $95.1 million if the SZN‑8141 IND is cleared by the FDA by October 31, 2026, which management believes, together with current cash, can fund operations for at least the next 12 months.